Xintituo Stelara Injection

Brand Name:新替妥 ®(Xintituo®)
Generic Name: Stelara
Strength: 10 mg per 0.5 mL vial, 1 vial per box
Manufacturer: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Marketing Authorization Holder: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Approval Date in China: February 11, 2025
Registration Number: 国药准字S20250012
Storage: Store and transport in the original package at 2–8°C, protected from light. Do not freeze or shake violently. Refer to the full package insert for detailed storage specifications.

Price&Cost:Contact Us now for the best price of Siltartoxatug(Xintituo)

1. Indications and Usage
Tetanus Prophylaxis: Indicated for passive immunity to prevent tetanus infection in adult patients with traumatic wounds requiring passive immunization.
Usage Restrictions: Safety and efficacy in patients <18 years of age have not been established.
2. Dosage and Administration
Route of Administration: Intramuscular injection ONLY.
Recommended Dosage: 10 mg administered as a single dose.
Critical Administration Instructions:
Site: Inject into the gluteal muscle.
Administration: No reconstitution is required prior to administration.
3. Mechanism of Action
Neutralization: This recombinant humanized monoclonal antibody binds to the AB fragment of tetanus toxin.
Inhibition: It blocks the transport of the toxin and inhibits its proteolytic activity on VAMP-2 (vesicle-associated membrane protein), thereby providing passive immunity against tetanus.
4. Safety and Warnings
Hypersensitivity: Contraindicated in patients with known severe allergies to the active ingredient or other serious allergic history.
Immunogenicity: As with all therapeutic proteins, anti-drug antibodies may develop, though no neutralizing antibodies were observed in clinical trials.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Treatment-emergent adverse events (≥0.5%) include drug-related adverse events, elevated liver enzymes (ALT/AST), positive urine occult blood, elevated blood glucose, and injection site reactions (pain, erythema, numbness, swelling).
Clinical Research Highlights: In a Phase III trial comparing this drug to human tetanus immunoglobulin (HTIG) for trauma patients, no serious adverse events occurred in either group, demonstrating a favorable safety profile.
6. Drug Interactions
Tetanus Vaccines: Concomitant use with adsorbed tetanus vaccines may reduce the total exposure of this drug by approximately 14%.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Siltartoxatug.
Appearance: Solution.
Packaging: Single-dose vials (e.g., 10 mg/0.5 mL).
Storage: Store according to standard pharmaceutical guidelines for biological products (refer to specific package insert for precise conditions).

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.